Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Idurote 2 Sulfatase (Alpha L Idurote Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Overview
Idurote 2 Sulfatase (Alpha L Idurote Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Idurote 2 Sulfatase (Alpha L Idurote Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Idurote 2 Sulfatase (Alpha L Idurote Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Companies Involved in Therapeutics Development
AngioChem Inc
AVROBIO Inc
Bioasis Technologies Inc
Deli Therapeutics Inc
Esteve Pharmaceuticals SA
GC Pharma
Homology Medicines Inc
Immusoft Corp
JCR Pharmaceuticals Co Ltd
RegenxBio Inc
Sigilon Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Idurote 2 Sulfatase (Alpha L Idurote Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Drug Profiles
AVRRD-05 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DNL-310 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EGT-301 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate Idurote 2 Sulfatase for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
History of Events
HMI-203 - Drug Profile
Product Description
Mechanism Of Action
History of Events
idursulfase - Drug Profile
Product Description
Mechanism Of Action
History of Events
idursulfase beta - Drug Profile
Product Description
Mechanism Of Action
History of Events
ISP-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
pabifusp alfa - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombint Idurote 2-Sulfatase Replacement for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
History of Events
RGX-121 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SIG-018 - Drug Profile
Product Description
Mechanism Of Action
History of Events
xB-3008 - Drug Profile
Product Description
Mechanism Of Action
Idurote 2 Sulfatase (Alpha L Idurote Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Dormant Products
Idurote 2 Sulfatase (Alpha L Idurote Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Discontinued Products
Idurote 2 Sulfatase (Alpha L Idurote Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Product Development Milestones
Featured News & Press Releases
Feb 15, 2022: JCR announces first patient dosed in phase 3 global clinical trial of JR-141 for treatment of MPS II (Hunter Syndrome)
Feb 10, 2022: Homology medicines announces presentations on HMI-203 investigatiol gene therapy for Hunter syndrome and broad applicability of AAVHSC platform for lysosomal storage disorders at the 18th Annual WORLDSymposium meeting
Feb 10, 2022: Deli Therapeutics announces continued progress in DNL310 program for MPS II (Hunter Syndrome) supporting planned initiation of Phase 2/3 clinical trial
Feb 09, 2022: REGENXBIO presents additiol positive interim data from phase I/II trial of RGX-121 for the treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium 2022
Feb 03, 2022: JCR Pharmaceuticals receives the WORLDSymposium new treatment award for IZCARGO (Pabifusp Alfa)
Feb 03, 2022: JCR pharmaceuticals to present posters on JR-141 at the 18th annual WORLDSymposium 2022
Feb 01, 2022: Deli therapeutics announces presentations on DNL310 (ETV:IDS) development program in MPS II (hunter syndrome) at the upcoming WORLDsymposium
Nov 29, 2021: Immusoft receives $4M in funding from the California Institute for Regenerative Medicine (CIRM)
Nov 08, 2021: AVROBIO to present preclinical data on AVRRD-05 at the 14th ICIEM Conference
Nov 03, 2021: AVROBIO receives Rare Pediatric Disease Desigtion from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
Nov 02, 2021: GC Green Cross desigted as a European orphan drug for the treatment of severe Hunter syndrome
Oct 20, 2021: Homology Medicines announces presentation of data supporting clinical programs in MPS II and PKU, including nonclinical and patient-focused research, at American Society of Human Genetics Meeting
Oct 18, 2021: Homology medicines initiates clinical trial for HMI-203, a one-time investigatiol gene therapy candidate for adults with MPS II (Hunter Syndrome)
Oct 18, 2021: JCR Pharmaceuticals Co : EMA grants PRIME desigtion for JR-141 for the treatment of Mucopolysaccharidosis type II (Hunter Syndrome)
Oct 15, 2021: JR-141 (Pabifusp Alfa) for Hunter syndrome notice on the publication of a nonclinical and clinical evidence in Intertiol Jourl of Molecular Sciences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AngioChem Inc, 2022
Pipeline by AVROBIO Inc, 2022
Pipeline by Bioasis Technologies Inc, 2022
Pipeline by Denali Therapeutics Inc, 2022
Pipeline by Esteve Pharmaceuticals SA, 2022
Pipeline by GC Pharma, 2022
Pipeline by Homology Medicines Inc, 2022
Pipeline by Immusoft Corp, 2022
Pipeline by JCR Pharmaceuticals Co Ltd, 2022
Pipeline by RegenxBio Inc, 2022
Pipeline by Sigilon Therapeutics Inc, 2022
Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Dormant Projects, 2022
Discontinued Products, 2022